Breaking News Instant updates and real-time market news.

PFE

Pfizer

$31.54

-0.15 (-0.47%)

, DAL

Delta Air Lines

$48.49

-0.75 (-1.52%)

07:30
11/29/16
11/29
07:30
11/29/16
07:30

Unusual put flow in option market yesterday

Notable put activity was cited Monday in Pfizer (PFE), Delta Air Lines (DAL), PayPal (PYPL), Horizon Pharma (HZNP), Sears (SHLD), Ciena (CIEN), LyondellBasell (LYB), Huntsman (HUN), and Quanta Services (PWR).

PFE

Pfizer

$31.54

-0.15 (-0.47%)

DAL

Delta Air Lines

$48.49

-0.75 (-1.52%)

PYPL

PayPal

$39.96

-0.3 (-0.75%)

HZNP

Horizon Pharma

$21.18

-0.31 (-1.44%)

SHLD

Sears

$12.60

-0.4 (-3.08%)

CIEN

Ciena

$21.43

-1.02 (-4.54%)

LYB

LyondellBasell

$85.58

-1.09 (-1.26%)

HUN

Huntsman

$18.62

-0.7 (-3.62%)

PWR

Quanta Services

$32.27

-0.61 (-1.86%)

  • 29

    Nov

  • 29

    Nov

  • 29

    Nov

  • 29

    Nov

  • 04

    Dec

  • 08

    Dec

  • 14

    Dec

PFE Pfizer
$31.54

-0.15 (-0.47%)

11/29/16
LEHM
11/29/16
UPGRADE
Target $38
LEHM
Overweight
Pfizer upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Geoff Meacham upgraded Pfizer to Overweight and raised its price target to $38 from $37. Meacham sees a greater likelihood that Pfizer will be able to access its cash overseas under the new administration, which could be used to acquire growth assets and return capital to shareholders.
11/02/16
11/02/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Pfizer (PFE) downgraded to Hold from Buy at Argus and to Market Perform from Outperform at BMO Capital. 2. BP (BP) downgraded to Hold from Buy at Societe Generale. 3. Corning (GLW) downgraded to Buy from Conviction Buy at Goldman with analyst Doug Clark saying the restocking phase of glass/TV cyclical recovery is now "well understood and largely behind us." 4. Adeptus Health (ADPT) downgraded to Underperform from Buy at BofA/Merrill, to Hold from Buy at Jefferies, and to Equal Weight from Overweight at Stephens. 5. Brookdale Senior Living (BKD) downgraded to Underperform from Neutral at BofA/Merrill, to Market Perform from Outperform at Wells Fargo, and to Outperform from Top Pick at RBC Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/02/16
ARGS
11/02/16
DOWNGRADE
ARGS
Hold
Pfizer downgradedon weaker outlook at Argus
As noted earlier, Argus downgraded Pfizer to Hold from Buy. Analyst Jacob Kilstein cited "recent pipeline setbacks, prospects for increased competition, and management's decision to shelve its business separation plan" as reasons for the downgrade.
11/02/16
LEER
11/02/16
NO CHANGE
LEER
Pfizer boco failure should not spillover to other PCSK9 antibodies, says Leerink
Leerink analyst Geoffrey Porges says that Pfizer's (PFE) announcement that it is discontinuing development of anti-PCSK9 antibody bococizumab is significant and may give investors pause regarding the entire anti-PCSK9 antibody class. However, the analyst notes that composite of views suggests Boco-specific factors led to disappointment and to the program discontinuation. Further, Porges does not believes investors should expect any similar effects in the longer term follow up with Amgen's (AMGN) Repatha or Regeneron (REGN)/Sanofi's (SNY) Praluent.
DAL Delta Air Lines
$48.49

-0.75 (-1.52%)

11/18/16
11/18/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Cisco (CSCO) coverage resumed with a Hold at Stifel. 2. UPS (UPS) was initiated with an Outperform at BMO Capital while the firm initiated FedEx (FDX) with a Market Perform. 3. Synchrony (SYF) was initiated with an Overweight at Stephens. The firm also initiated American Express (AXP) and Discover (DFS) with an Underweight. 4. American Airlines (AAL), Delta Air Lines (DAL), Southwest (LUV) and Allegiant Travel (ALGT) were initiated with a Buy at Citi while the firm initiated JetBlue (JBLU), United Continental (UAL), Alaska Air (ALK), and Hawaiian Holdings (HA) with a Neutral. 5. Juniper (JNPR) coverage resumed at Stifel. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/18/16
SBSH
11/18/16
INITIATION
Target $61
SBSH
Buy
Delta Air Lines initiated with a Buy at Citi
Citi analyst Kevin Crissey started Delta Air Lines with a Buy rating and $61 price target.
10/17/16
ARGS
10/17/16
NO CHANGE
ARGS
Delta Air Lines price target lowered to $48 from $60 at Argus
Argus analyst David Coleman cut his price target on Delta after the company reported results that beat the consensus estimate but came in below Coleman's forecast. Coleman says that the company is continuing to benefit from strong industry fundamentals, and he still believes that the company's results will improve over time. He keeps a Buy rating on the stock.
10/11/16
BERN
10/11/16
INITIATION
BERN
Airlines initiated at Bernstein
Bernstein analyst David Vernon initiated coverage of the U.S. airline sector, saying that he is "bullish on the sector" and asserting that it has "favorable..dynamics." He expects the sector's stocks to have "higher average highs and higher average lows over time," driven partly by its investments in return enhancing programs, revenue enhancing initiatives, and "a stronger outlook for longer term capital return" which isn't reflected in valuation, according to the analyst. Vernon recommends owning airlines that have "less financial and operating leverage." He says that he is "favorably disposed" to Southwest (LUV) and Delta Air Lines (DAL), which he says have high returns and low leverage, and is less upbeat on United Continental (UAL), which he says has higher operating leverage and execution risk. He is bearish on American Airlines (AAL), as he thinks that its capacity growth and financial leverage create significant risk. The analyst started coverage of Southwest with an Outperform rating and a $51 price target. He initiated coverage of Delta and United Continental with Market Perform ratings and $43 and $55 price targets, respectively. He launched American with a $31 price target and Underperform rating.
PYPL PayPal
$39.96

-0.3 (-0.75%)

11/15/16
JEFF
11/15/16
NO CHANGE
JEFF
Jefferies sees attractive entry points for Payments stocks
Payments stocks Visa (V), MasterCard (MA), PayPal (PYPL), Global Payments (GPN), Vantiv (VNTV) have been big underperformers since Election Day as investors rotate into core Financials, Jefferies analyst Jason Kupferberg tells investors in a research note. The corrections of up to 10% are not warranted fundamentally, the analyst contends. Kupferberg sees attractive entry points at current levels and highlights PayPal and Visa as his top picks.
10/21/16
10/21/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Microsoft (MSFT) upgraded to Buy from Hold at Wunderlich and to Outperform from Market Perform at William Blair. 2. Reynolds American (RAI) upgraded to Buy from Hold at Berenberg. 3. eBay (EBAY) upgraded to Buy from Long-Term Buy at Hilliard Lyons. 4. BNY Mellon (BK) upgraded to Outperform from Market Perform at Keefe Bruyette with analyst Brian Kleinhanzl citing improving fundamentals following the company's third quarter results. 5. PayPal (PYPL) upgraded to Buy from Hold at Stifel with analyst Scott Devitt saying the company reported "solid" third quarter results and should deliver "stable consistent, and robust" growth going forward. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/21/16
STFL
10/21/16
UPGRADE
STFL
Buy
PayPal upgraded on growth outlook, multiple catalysts at Stifel
As noted earlier, Stifel upgraded PayPal to Buy from Hold. Analyst Scott Devitt says that the company reported "solid" Q3 results and should deliver "stable consistent, and robust" growth going forward. He thinks that the risk facing the company has dropped significantly recently, and he has become more upbeat on its longer term outlook in light of recent events, including its deals with credit card networks. Devitt recommends aggressively buying the stock. Target $49.
10/21/16
BARD
10/21/16
NO CHANGE
Target $48
BARD
Outperform
PayPal medium-term guidance removes overhang, says Baird
Baird analyst Colin Sebastian noted PayPal reported Q3 results largely in-line with Street expectations, which reflected continuing positive trends driven by secular e-commerce growth and increasing market share. The analyst noted PayPal provided updated three-year financial targets that reflect efforts to gain incremental revenues and cost efficiencies to offset margin headwinds. Sebastian reiterated his Outperform rating and $48 price target on PayPal shares.
HZNP Horizon Pharma
$21.18

-0.31 (-1.44%)

11/28/16
SBSH
11/28/16
UPGRADE
Target $25
SBSH
Buy
Horizon Pharma upgraded to Buy from Neutral at Citi
Citi analyst Liav Abraham upgraded Horizon Pharma to Buy after resuming coverage of the name. The analyst views the risk/reward as favorable into the upcoming pivotal data for Actimmune in Friederich's Ataxia. The data are expected in late December. Abraham raised her price target for the shares to $25 from $21.
11/28/16
BMOC
11/28/16
NO CHANGE
BMOC
Horizon Pharma risk/reward positive into Phase 3 data, says BMO Capital
BMO Capital analyst Gary Nachman says that the risk/reward ratio for Horizon is positive going into the Phase 3 data for its Actimmune drug in Friedreich's Ataxia. The analyst thinks that there is only a 50% chance that the data will be successful;. However, he says that the risk/reward ratio is "favorable," based on how he thinks the shares will perform in the wake of the event. He keeps a $29 price target and an Outperform rating on the shares.
11/28/16
11/28/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Deere (DE) upgraded to Neutral from Underweight at Piper Jaffray with analyst Brett Wong saying investors will likely continue to pay "lofty multiples" since a bottom of the cycle is close. 2. ConocoPhillips (COP) upgraded to Conviction Buy from Neutral at Goldman with analyst Neil Mehta saying ConocoPhillips offers the most attractive free cash yield among U.S. majors/E&P and believes the company will grow its production through the ned of the decade. 3. Comerica (CMA) upgraded to Buy from Hold at Jefferies with analyst Ken Usdin saying the company's earnings are likely to benefit more than peers from higher short-term interest rates and a potentially lower Federal tax rate. 4. DuPont Fabros (DFT) upgraded to Outperform from Neutral at Baird with analyst David Rodgers citing its future development opportunity, solid corporate execution, and valuation. 5. Horizon Pharma (HZNP) upgraded to Buy from Neutral at Citi analyst Liav Abraham saying the risk/reward as favorable into the upcoming pivotal data for Actimmune in Friederich's Ataxia. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/27/16
PIPR
10/27/16
NO CHANGE
Target $33
PIPR
Overweight
Piper survey suggests growth for Horizon's Krystexxa
Piper Jaffray analyst David Amsellem says his survey of 25 rheumatologists who treat patients with chronic refractory gout and who are at least familiar with Horizon Pharma's Krystexxa suggest usage of the product is likely to broaden. The analyst points out that 76% of the respondents believe Krystexxa is a very effective option for the treatment of chronic refractory gout. He continues to believe Horizon is well positioned to deliver long-term annual earnings growth at least in the mid-teens. Amsellem sees an attractive valuation for Horizon shares and reiterates an Overweight rating on the name with a $33 price target.
SHLD Sears
$12.60

-0.4 (-3.08%)

02/09/16
EVER
02/09/16
NO CHANGE
EVER
Sears is not a viable retailer, says Evercore ISI
Evercore ISI does not believe Sears is a viable retailer in its current form, and a liquidity event is a matter of when, not if. The firm's analyst said Sears' cash situation has deteriorated, making additional debt issuance more likely in 2016 with a larger liquidity event possible in 2017. Evercore has a base case of $4 per share on Sears based on its SOTP analysis.
02/09/16
EVER
02/09/16
NO CHANGE
EVER
Sell
Sears liquidity event a matter of 'when, not if,' says Evercore ISI
Evercore ISI analyst Greg Melich said the preliminary Q4 financials released by Sears showed comparable sales were worse than he expected at the flagship brand and at Kmart and that its margins were also worse than he thought. Sear's cash situation has gotten worse, making additional debt issuance more likely in 2016, Melich tells investors, adding that he believes "a liquidity event is a matter of when not if," and may be possible in 2017 at the current burn rate. The analyst keeps a Sell rating on Sears shares.
03/17/16
EVER
03/17/16
NO CHANGE
EVER
Sears could trade as low as $3 per share, says Evercore ISI
CIEN Ciena
$21.43

-1.02 (-4.54%)

09/06/16
NEED
09/06/16
NO CHANGE
Target $30
NEED
Buy
Needham more positive on Ciena business outlook
Needham analyst Alex Henderson has a more positive perspective on Ciena's shares and the company's business outlook following its earnings release. Given the accelerating demand, strengthening metro and more end-to-end with Flex Coherent, the analyst believes Ciena is "uniquely positioned for growth" with expanding margins. He reiterates a Buy rating and $30 price target on the shares.
11/14/16
DBAB
11/14/16
UPGRADE
Target $27
DBAB
Buy
Ciena upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Vijay Bhagavath upgraded Ciena to Buy and raised his price target for the shares to $27 from $20. The analyst says his proprietary analysis indicates "solid order trends" in 100G+ Optical at Hyperscale Clouds for Datacenter Interconnects and Sub-sea.
10/06/16
MKMP
10/06/16
NO CHANGE
Target $28
MKMP
Buy
Ciena's Q4 orders are strong, says MKM Partners
MKM Partners analyst Michael Genovese said Ciena mid-quarter field checks suggest Q4 orders are strong with incremental order acceleration in the Subseas market in the US, Asia-Pacific, and in the US Metro market. Genovese believes investor gross margin fears are overblown and reiterates his Buy rating and a $28 price target.
09/30/16
STFL
09/30/16
INITIATION
STFL
Hold
Ciena coverage resumed with a Hold at Stifel
Stifel analyst Patrick Newton resumed coverage of Ciena with a Neutral rating. He says that consensus estimates for the company adequately reflect its growth opportunities. Target $23.
LYB LyondellBasell
$85.58

-1.09 (-1.26%)

06/27/16
06/27/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on the today's top five analyst downgrades with this list compiled by The Fly: 1. UBS (UBS) downgraded to Underweight from Neutral by JPMorgan analyst Kian Abouhossein, who cut his estimates for European banks following the Brexit vote. The analyst also downgraded Barclays (BCS) Deustche Bank (DB), Lloyds Banking (LYG) and Credit Suisse (CS) to Neutral from Overweight and RBS (RBS) to Underweight from Neutral. Barclays was also downgraded at Jefferies, BofA/Merrill and Exane BNP Paribas, RBS was also downgraded at RBC Capital, Societe Generale, Jefferies, BofA/Merrill and Exane BNP Paribas and Lloyds was also downgraded at Barclays and BofA/Merrill. 2. Fiat Chrysler (FCAU) downgraded to Buy from Conviction Buy at Goldman by analyst Stefan Burgstaller, who cited slower European volume growth, a weaker North American market outlook in out years and updated currency assumptions following the UK referendum. The analyst cut his price target for the shares to $8 from $12.80. 3. LyondellBasell (LYB) downgraded to Sector Perform from Outperform at RBC Capital by analyst Arun Viswanathan, who sees limited near-term catalysts given soft ethylene and polyethylene momentum and is cautious on the large increase of ethylene capacity in 2017/18 and potentially higher ethane prices, combined with higher capex needs. The analyst cut his price target to $84 from $100. 4. AGCO (AGCO) downgraded to Underweight from Neutral at JPMorgan by analyst Ann Duignan, who cited weakening fundamentals in European agriculture. The company has the greatest exposure to Europe in our Machinery coverage, Duignan told investors in a research note. She cut her price target for the shares to $44 from $47. The analyst this morning also downgraded PACCAR (PCAR) and Parker-Hannifin (PH) to Underweight from Neutral. 5. NXP Semiconductors (NXPI) downgraded to Neutral from Buy at BofA/Merrill by analysts led by Vivek Arya, who lowered his price target to $90 from $100. Analysts lowered estimates given the company's heavy exposure to the Auto segment and industrial/infrastructure segment and likely pressure on top-line growth from Brexit. The analyst is less confidence NXP can grow top line year-over-year in 2016/17 and said the Freescale (FSL) acquisition and shareholder sales creates an overhang. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/27/16
RBCM
06/27/16
DOWNGRADE
Target $84
RBCM
Sector Perform
LyondellBasell downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital analyst Arun Viswanathan downgraded LyondellBasell to Sector Perform and lowered its price target to $84 from $100. The analyst sees limited near-term catalysts given soft ethylene and polyethylene momentum and is cautious on the large increase of ethylene capacity in 2017/18 and potentially higher ethane prices, combined with higher capex needs.
06/23/16
JPMS
06/23/16
DOWNGRADE
Target $80
JPMS
Neutral
LyondellBasell downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Jeffrey Zekauskas downgraded LyondellBasell to Neutral from Overweight citing his expectations for increased capital expenditures and the fact that ethane now trades at a premium to its fuel value. Zekauskas lowered his price target on LyondellBasell shares to $80 from $100.
10/13/16
TUDR
10/13/16
INITIATION
Target $95
TUDR
Buy
LyondellBasell initiated with a Buy at Tudor Pickering
Tudor Pickering analyst Matthew Blair initiated LyondellBasell with a Buy and a $95 price target.
HUN Huntsman
$18.62

-0.7 (-3.62%)

03/07/16
UBSW
03/07/16
NO CHANGE
Target $14
UBSW
Buy
Huntsman shares offer compelling opportunity, says UBS
UBS said Huntsman shares offer a compelling opportunity, citing the earnings potential of its cyclical businesses and its review of alternatives for its TiO2 division. UBS reiterated its Buy rating and $14 price target on Huntsman shares.
02/11/16
KEYB
02/11/16
DOWNGRADE
KEYB
Sector Weight
Huntsman downgraded to Sector Weight from Overweight at KeyBanc
07/11/16
NOMU
07/11/16
NO CHANGE
NOMU
Buy
Olin and Huntsman remain Top Picks for 2H 2016 at Nomura
Nomura analyst Aleksey Yefremov said Olin (OLN) and Huntsman (HUN) remain Top Picks heading into 2H 2016. The analyst sees stronger evidence of recovery in chlor-alkali and TiO2, combined with above-average FCF yields for both Buy rated names.
PWR Quanta Services
$32.27

-0.61 (-1.86%)

11/18/16
AVON
11/18/16
DOWNGRADE
Target $31.5
AVON
Market Perform
Quanta Services downgraded to Market Perform from Outperform at Avondale
Avondale analyst Daniel Mannes downgraded Quanta Services to Market Perform with a $31.50 price target citing full valuation ans sees some risk of a 2H 2017 project gap in O&G as ACP moves into construction in 2018 which may result in management to be cautious on 2017 guidance.
08/05/16
STFL
08/05/16
UPGRADE
STFL
Buy
Quanta Services upgraded on favorable set-up at Stifel
As noted earlier, Stifel upgraded Quanta to Buy from Hold. Analyst Noelle Dilts is upbeat on the company's core transmission market and expects "a significant potion" of its power plant write downs to be recovered this quarter. Target $28.
11/15/16
11/15/16
UPGRADE
Target $40

Outperform
Quanta Services upgraded to Outperform at Baird
As previously reported, Baird analyst Andrew Wittmann upgraded Quanta Services to Outperform from Neutral, calling its exposure to pipeline infrastructure, and the Keystone XL project specifically, a key catalyst following the election of Donald Trump. The analyst noted his view is "tactically oriented" and he would look to revisit it if Quanta shares quickly rise towards his new $40 price target, which is up from a prior target of $30.
11/15/16
BARD
11/15/16
UPGRADE
BARD
Outperform
Quanta Services upgraded to Outperform from Neutral at Baird

TODAY'S FREE FLY STORIES

SEAS

SeaWorld

$15.65

-0.16 (-1.01%)

20:01
06/25/17
06/25
20:01
06/25/17
20:01
Hot Stocks
SeaWorld receives subpoenas, forms special committee over 'Blackfish' statements »

SeaWorld stated in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$155.07

1.67 (1.09%)

19:57
06/25/17
06/25
19:57
06/25/17
19:57
Periodicals
Facebook plans to offer TV-quality content by late summer, WSJ says »

Facebook is in talks with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

FRO

Frontline

$5.59

0.08 (1.45%)

, GNRT

Gener8 Maritime

$6.12

0.21 (3.55%)

19:50
06/25/17
06/25
19:50
06/25/17
19:50
Periodicals
Frontline abandons plans to buy Gener8, WSJ says »

Frontline (FRO) has…

FRO

Frontline

$5.59

0.08 (1.45%)

GNRT

Gener8 Maritime

$6.12

0.21 (3.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSRGY

Nestle

$84.83

0.4 (0.47%)

18:46
06/25/17
06/25
18:46
06/25/17
18:46
Hot Stocks
Third Point confirms $3.5B stake in Nestle, urges change at company »

In a letter published…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Wal-Mart

$74.84

-0.68 (-0.90%)

18:23
06/25/17
06/25
18:23
06/25/17
18:23
Periodicals
Wal-Mart initially clamped down on alcohol, swearing at Jet.com, WSJ says »

After Wal-Mart acquired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$965.59

8.5 (0.89%)

, GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

17:55
06/25/17
06/25
17:55
06/25/17
17:55
Periodicals
EU plans EUR1B fine against Google this week, FT reports »

The EU plans to levy a…

GOOG

Alphabet

$965.59

8.5 (0.89%)

GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

NSRGY

Nestle

$84.83

0.4 (0.47%)

17:37
06/25/17
06/25
17:37
06/25/17
17:37
Periodicals
Dan Loeb's Third Point targets Nestle, Bloomberg says »

Nestle is being targeted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LNG

Cheniere Energy

$47.62

0.34 (0.72%)

17:27
06/25/17
06/25
17:27
06/25/17
17:27
Hot Stocks
Cheniere Energy announces commencement of Korea Gas LNG contract »

Cheniere Energy and Korea…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIA

Viacom

$39.15

0.1 (0.26%)

, VIAB

Viacom

$34.11

-0.01 (-0.03%)

16:20
06/25/17
06/25
16:20
06/25/17
16:20
Hot Stocks
Box Office Battle: Fifth 'Transformers' film ekes out $45M in franchise low »

Viacom's (VIA)…

VIA

Viacom

$39.15

0.1 (0.26%)

VIAB

Viacom

$34.11

-0.01 (-0.03%)

TWX

Time Warner

$99.70

0.3 (0.30%)

DIS

Disney

$104.36

0.14 (0.13%)

LGF.A

Lionsgate

$27.07

0.31 (1.16%)

LGF.B

Lionsgate

$25.38

0.34 (1.36%)

FOX

21st Century Fox

$26.93

0.3 (1.13%)

FOXA

21st Century Fox

$27.19

0.22 (0.82%)

SNE

Sony

$38.52

0.11 (0.29%)

CMCSA

Comcast

$39.50

-0.44 (-1.10%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 27

    Jul

  • 03

    Aug

  • 08

    Aug

GSK

GlaxoSmithKline

$44.29

0.13 (0.29%)

14:42
06/25/17
06/25
14:42
06/25/17
14:42
Hot Stocks
GlaxoSmithKline granted Orphan designation for multiple myeloma treatment »

The FDA granted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHVN

Biohaven Pharmaceutical

$25.33

-0.13 (-0.51%)

14:40
06/25/17
06/25
14:40
06/25/17
14:40
Hot Stocks
Biohaven granted Orphan designation for Rett syndrome treatment »

The FDA granted Biohaven…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESALY

Eisai

$56.42

-0.075 (-0.13%)

14:37
06/25/17
06/25
14:37
06/25/17
14:37
Hot Stocks
Eisai unit receives Orphan designation for myelomonocytic leukemia treatment »

The FDA has granted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTNR

Partner Communications

$5.25

0.1123 (2.19%)

14:23
06/25/17
06/25
14:23
06/25/17
14:23
Hot Stocks
Partner Communications executes early loan repayments, sees Q2 expense »

Partner Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RARX

RA Pharmaceuticals

$23.01

0.01 (0.04%)

14:21
06/25/17
06/25
14:21
06/25/17
14:21
Hot Stocks
RA Pharma: Presentation on complement inhibitors supports continued development »

Ra Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

VSTM

Verastem

$2.32

-0.06 (-2.52%)

14:17
06/25/17
06/25
14:17
06/25/17
14:17
Hot Stocks
Verastem reports long-term follow up data from 'DYNAMO' study »

Verastem announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 29

    Jun

  • 11

    Jul

BMY

Bristol-Myers

$56.64

-0.69 (-1.20%)

14:09
06/25/17
06/25
14:09
06/25/17
14:09
Hot Stocks
Bristol-Myers reports four-year follow up data from 'ELOQUENT-2' study »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 24

    Sep

AGIO

Agios Pharmaceuticals

$59.18

1.76 (3.07%)

, CELG

Celgene

$134.31

0.63 (0.47%)

14:05
06/25/17
06/25
14:05
06/25/17
14:05
Hot Stocks
Agios Pharmaceuticals reports new data from Phase 1/2 trial of IDHIFA »

Agios Pharmaceuticals…

AGIO

Agios Pharmaceuticals

$59.18

1.76 (3.07%)

CELG

Celgene

$134.31

0.63 (0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGIO

Agios Pharmaceuticals

$59.18

1.76 (3.07%)

14:00
06/25/17
06/25
14:00
06/25/17
14:00
Hot Stocks
Agios reports updated Phase 2 data on AG-348, sees 1H18 pivotal program »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNOW

Intrawest Resorts

$23.65

0.04 (0.17%)

13:53
06/25/17
06/25
13:53
06/25/17
13:53
Hot Stocks
Intrawest Resorts says Hart-Scott-Rodino merger waiting period expires »

Intrawest Resorts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CI

Cigna

$169.61

-1.07 (-0.63%)

13:31
06/25/17
06/25
13:31
06/25/17
13:31
Periodicals
Cigna could gain over 15% by end of next year, Barron's says »

The GOP healthcare plan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FL

Foot Locker

$48.03

0.53 (1.12%)

, NKE

Nike

$52.85

0.45 (0.86%)

13:26
06/25/17
06/25
13:26
06/25/17
13:26
Periodicals
Potential Nike-Amazon deal another negative for Foot Locker, Barron's says »

A potential direct-sale…

FL

Foot Locker

$48.03

0.53 (1.12%)

NKE

Nike

$52.85

0.45 (0.86%)

AMZN

Amazon.com

$1,003.74

2.44 (0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 29

    Jun

RHT

Red Hat

$99.42

0.54 (0.55%)

13:15
06/25/17
06/25
13:15
06/25/17
13:15
Periodicals
Red Hat may eke out double-digit returns, Barron's says »

Red Hat investors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALXN

Alexion

$126.07

-0.16 (-0.13%)

, UTHR

United Therapeutics

$131.59

-0.11 (-0.08%)

13:01
06/25/17
06/25
13:01
06/25/17
13:01
Periodicals
Alexion, United Therapeutics worth a look, Barron's says »

After the recent jump in…

ALXN

Alexion

$126.07

-0.16 (-0.13%)

UTHR

United Therapeutics

$131.59

-0.11 (-0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 23

    Oct

AIZ

Assurant

$101.25

0.99 (0.99%)

12:32
06/25/17
06/25
12:32
06/25/17
12:32
Periodicals
Assurant could double as investors reevaluate company, Barron's says »

Assurant is shifting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCR

NCR Corp.

$38.64

0.09 (0.23%)

12:27
06/25/17
06/25
12:27
06/25/17
12:27
Periodicals
NCR Corp. could gain 30% in a year, Barron's says »

Shares of NCR Corp. could…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.